MannKind Corporation Reports Third Quarter 2026 Financial Results
MannKind Corporation announced its financial results for the third quarter of 2026, highlighting the commercial progress of Furoscix ReadyFlow and Afrezza.
Stocks · News reference
Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10
Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MannKind Corporation to Report Third Quarter 2026 Financial Results on November 5, 2026
MannKind Corporation announced it will release its third quarter 2026 financial results after market close on November 5, 2026, followed by a conference call.
Cantor Fitzgerald Maintains $8.00 Price Target on MannKind
Cantor Fitzgerald has reaffirmed its $8.00 per share price target for MannKind Corporation.
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.
MannKind to Participate in the Chardan Healthcare Conference
MannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions.